TSXV: FIRE

TORONTO, Dec. 18, 2017 /CNW/ – Supreme Pharmaceuticals Inc. (“Supreme or the “Company“) (TSXV:FIRE) is pleased to announce the purchase of an approximately six acre property adjacent to the 7ACRES facility in Kincardine, Ontario. Supreme expects to build an indoor cultivation facility (“Lot 16“) to produce high quality, “California-Style” cannabis for the premium product segment.

Supreme is currently in the design phase of the project and intends to break ground in the summer of 2018. The Company intends to complete the project by the end of 2019. Supreme anticipates that Lot 16, once fully operational and subject to licensing by Health Canada, will produce 10,000 kg per year of premium “California-Style” indoor cannabis. Supreme intends on using lighting, HVAC and irrigation infrastructure ideally suited to cultivating premium cannabis cultivars. Lot 16 is expected to employ Supreme’s proprietary post-harvest processes to produce dried cannabis flower that is slow-dried, artisanal cured and finished by hand. Supreme intends to market the Lot 16 dried cannabis flower as an ultra-premium consumer product and pursue favorable pricing economics with current and future retail partners. Supreme acquired the Lot 16 land for $1,927,200.

“Supreme’s goal is to be synonymous with quality and a leader in the premium segment for cannabis flower,” said John Fowler, CEO of Supreme. “Since inception, we have been resolute in our belief that cannabis consumers are quality driven and willing to pay a premium for cannabis flowers with exceptional qualities. We believe the premium product segment for dried flower will be significantly under-supplied in Canadagiven the industry focus on low-cost cannabis and traditional greenhouse infrastructure. Lot 16 represents the next step in the development of our Kincardine Campus, and additional progress towards Supreme being a dominant player in the premium segment for dried cannabis flower in Canada.”

John Fowler, CEO and Director

About Supreme

Supreme is a Canadian publicly traded company committed to becoming a leading cultivator and distributor of sun grown cannabis through its wholly-owned subsidiary 7ACRES. 7ACRES is a federally licensed producer of medical cannabis pursuant to the ACMPR operating inside a 342,000 sq. ft. Hybrid Greenhouse facility. The Hybrid Greenhouse combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Please visit www.supreme.ca and www.7acres.com for more information.

Forward-Looking Information

Certain statements made in this press release may constitute forward-looking information under applicable securities laws. These statements may relate to anticipated events or results and include, but are not limited to, expectations regarding, the construction and design of the Lot 16 facility, the ability for Supreme to finance the construction of the Lot 16 facility economically, licensing risk relating to the Lot 16 facility, our regulatory environment and potential changes in law generally, expectations regarding our production capacity at the Lot 16 facility, technology and operations and other statements that are not historical facts. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information. Often, but not always, forward-looking statements can be identified by the use of forward-looking terminology such as “may” “will”, “expect”, “believe”, “estimate”, “plan”, “could”, “should”, “would”, “outlook”, “forecast”, “anticipate”, “foresee”, “continue” or the negative of these terms or variations of them or similar terminology. Forward-looking statements are current as of the date they are made and are based on applicable estimates and assumptions made by us at the relevant time in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. However, we do not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. There can be no assurance that such estimates and assumptions will prove to be correct. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the factors discussed in the “Risks and Uncertainties” section of the Company’s Management’s Discussion & Analysis dated November 27, 2017 (“MD&A”). A copy of the MD&A and the Company’s other publicly filed documents can be accessed under the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. The Company cautions that the list of risk factors and uncertainties described in the MD&A is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Supreme Pharmaceuticals Inc.